All posts by medical

Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 – Yahoo Finance

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its second quarter 2020 financial results on Thursday, July 30, 2020 after the close of financial markets. Following the announcement, Company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:

Thursday, July 30, 20201:30 p.m. Pacific Time / 4:30 p.m. Eastern Time

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEVTM (enfortumab vedotin-ejfv) use the Companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSATM (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The Company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005173/en/

Contacts

Investors Peggy Pinkston(425) 527-4160ppinkston@seagen.com

Media Monique Greer(425) 527-4641mgreer@seagen.com

Read more from the original source:
Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2020 Financial Results on July 30, 2020 - Yahoo Finance

Kernel raises $53M to expand access to its Neuroscience as a Service platform – VatorNews

The company was founded by Braintree's Bryan Johnson

Kernelis a company pioneering a new space:Neuroscience as a Service (NaaS), in which it noninvasively records brain activity, allowing its customers to measure and quantify cognition on-demand.

It's a fairly new technology, and it's caught the interest of investors, who just poured $53 million into the company, it was announced on Thursday. The round was led by General Catalyst, with participation from Khosla Ventures, Eldridge, Manta Ray Ventures, Tiny Blue Dot and Bryan Johnson, founder and CEO of Kernel.

While this is being called a Series C round, it's actually the first outside funding the company has taken; until now, it had raised $54 million, all from Johnson's own pocket, bringing its total funding to $107 million. Johnson was previously the founder, chairman and CEO of payment company Braintree, which was acquired by eBay for $800 million in 2013.

Founded in 2016, Kernel's platform is powered by two brain recording technologies: one is called "Flux," which is short for "magnetic flux." It detects the magnetic fields generated by collective neural activity in the brain. The other is called "Flow," short for "blood flow," and it detects cortical hemodynamics, which is representative of neural activity.

Kernel's customers can use the technology to do things such as explore biomarkers, but the company is also getting a lot of interest from customers trying to use it for improving machine learning algorithms for such applications as image recognition and voice recognition.

One group that Kernel is working with, for example, is trying to quantify a neural assessment, instead of relying on qualitative questions and self-reporting.Another company is using the neural data to improve image recognition algorithms; Kernal is able to provide vast amounts of brain data that can be fed to a deep neural network for a much higher representation of an image.

Along with the funding, it was revealed that Quentin Clark, Managing Director at General Catalyst, has joined the Board of Directors at Kernel.

"The vision fueling Kernel is one of the most audacious imaginable." Clark said in a statement. "But that ambition has a passionate and committed founder and team, and pragmatic engineering work to back it up. Kernel's engineering accomplishments have the potential to enable more neuroscience progress in the next few years than has been accomplished in the last few decades."

Read more:
Kernel raises $53M to expand access to its Neuroscience as a Service platform - VatorNews

Neuroscience Antibodies & Assays Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 – 3rd Watch News

New Jersey, United States,- Verified Market Research sheds light on the market scope, potential, and performance perspective of the Neuroscience Antibodies & Assays Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the Neuroscience Antibodies & Assays market.

The research study includes the latest updates about the COVID-19 impact on the Neuroscience Antibodies & Assays sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Neuroscience Antibodies & Assays manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Neuroscience Antibodies & Assays market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Neuroscience Antibodies & Assays sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Neuroscience Antibodies & Assays, the report covers-

Bytype1

In Market Segmentation by Applications of the Neuroscience Antibodies & Assays, the report covers the following uses-

Byapplication1

To get Incredible Discounts on this Premium Report, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=28342&utm_source=3WN&utm_medium=003

The Neuroscience Antibodies & Assays market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Neuroscience Antibodies & Assays market.

This study analyzes the growth of Neuroscience Antibodies & Assays based on the present, past and futuristic data and will render complete information about the Neuroscience Antibodies & Assays industry to the market-leading industry players that will guide the direction of the Neuroscience Antibodies & Assays market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Neuroscience Antibodies & Assays market. Additionally, it includes a share of each segment of the Neuroscience Antibodies & Assays market, giving methodical information about types and applications of the market.

Reasons for Buying Neuroscience Antibodies & Assays Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Neuroscience Antibodies & Assays market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.verifiedmarketresearch.com/product/Neuroscience-Antibodies-&-Assays-Market/?utm_source=3WN&utm_medium=003

In the end, the Neuroscience Antibodies & Assays market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the Neuroscience Antibodies & Assays market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email: [emailprotected]

Follow this link:
Neuroscience Antibodies & Assays Market Growth By Manufacturers, Countries, Types And Application, End Users And Forecast To 2026 - 3rd Watch News

BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from…

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation

NEW HAVEN, Conn., July 09, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (BTI or Company) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced that the Company has initiated an expanded access program at Massachusetts General Hospital (MGH) to provide its investigational drug, BXCL501, the Companys proprietary sublingual thin-film formulation of dexmedetomidine (Dex), to critically ill patients diagnosed with COVID-19 in the intensive care unit ("ICU") that may require calming or arousable sedation.

We are pleased to support clinicians at MGH as they manage an in-flux of COVID-19 patients, commented Vimal Mehta, Ph.D., Chief Executive Officer of BTI. COVID-19 primarily affects the respiratory system, with the severely ill often requiring mechanical ventilation. As a result of critical illness and the medical coma that is necessary for mechanical ventilation, patients frequently develop delirium and agitation, causing worse clinical outcomes and extended hospital stays. BXCL501 is being studied in advanced clinical trials to treat acute agitation, and we believe it has the potential, if approved, to help physicians treat patients that may be struggling with agitation or delirium.

Facilitated by the U.S. Food and Drug Administration (FDA), expanded access, also known as compassionate use, provides an opportunity for patients to receive an investigational treatment prior to regulatory approval when there are no comparable or satisfactory therapeutic alternatives available.

Being on the frontlines of this pandemic, our intensivists have witnessed firsthand the high numbers of critically ill patients diagnosed with COVID-19 and ICU delirium, added Seun Johnson-Akeju, M.D., M.M.Sc., Anesthetist-in-Chief of the Department of Anesthesia, Critical Care and Pain Medicine at the Massachusetts General Hospital. The COVID-19 surge caused an acute shortage of medications for managing agitation. We are hopeful that BXCL501 will improve the clinical outcomes of critically ill patients diagnosed with COVID-19 that are struggling with agitation and ICU delirium.

About BXCL501

BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of mild to moderate agitation in schizophrenia, bipolar disorder, and dementia.

A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in the Phase 1b/2 TRANQUILITY trial for the treatment of agitation associated with dementia, as well as the Phase 1b/2 RELEASE trial for the treatment of opioid withdrawal symptoms.

About BioXcel Therapeutics, Inc.:

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the evaluation of the Companys investigational drug, BXCL501, in the treatment of COVID-19 patients. When used herein, words including anticipate, being, will, plan, may, continue, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI's current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain.

BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption Risk Factors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented by its Current Report on Form 8-K filed on April 14, 2020, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SECs website at http://www.sec.gov and the Investors page of its website atwww.bioxceltherapeutics.com.

These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent managements estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTIs views as of any date subsequent to the date of this press release.

Contact Information:BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com

Investor Relations:John Grazianojgraziano@troutgroup.com1.646.378.2942

Media:Julia Deutschjdeutsch@troutgroup.com1.646.378.2967

More here:
BioXcel Therapeutics Announces Compassionate Use Program at Massachusetts General Hospital for BXCL501 to Treat COVID-19 Patients Suffering from...

I Chose Protesting for Black Lives Matter Over Writing My PhD Dissertation – Union of Concerned Scientists

These past few weeks,Ivehad to make a choice between writing my doctoral dissertation and protesting for the safety and protection of Black Lives. I chose the latter.

I began my PhD program in July of 2016, a few weeks after the deaths ofPhilando CastileandAlton Sterlingwho were both murdered by police officers. Not too long after, I attended my first graduate program retreat, which happened to be at an African American History museum. During the retreat, I felt more secluded in my Blackness as I noticed that many of my peers did not understand that we are still living through many of the same racial injustices depicted in the museum. A desensitizationin regards tothese instances that seem so long ago to White people, but have impacted me for 26 years of my life. I felt traumatized again by the history of my ancestors and plagued with the current police killings of innocent Black Americans today.

This is just one example of many such experiences throughout my PhD program.

We are currently living in the digital age of police brutality where incidents of unarmed Black people have been recorded for social media viewing. As a Neuroscience Doctoral Candidate, I have been expected to remain productive by analyzing and collecting data. However, as a Black woman I have also had to deal with conflicting perspectives on how I am expected to proceed when I am emotionallyexhaustedand my mental health is suffering. I inherited the sorrows of my ancestors as I have been filled with grief over the most recent murders ofGeorge Floyd,Breonna Taylor,AhmaudArbery,Tony McDade, andSean Reed. I have not been afforded the luxury of ignoring these incidents as systemic racism chokes the air that I breathe.

My non-Black peers and professors are finally attempting to understand my experience as a Black woman scientist. However, what needs to be understood is that systemic racism is embedded in the history of science and is still present today. In 2017, I organized a workshop on Microaggressions in STEM as a way for graduate students and faculty to understand their own unconscious biases. A few days before the event, someone RSVPd under the alias of Richard Spencer (a well-known white supremacist) and threatened to disrupt the event along with 10 others. The other organizers and I reported this threat to our schools police department and were met with rehearsed dialogue about how racism is wrong without concrete actions to support underrepresented minorities at our institution long term.

The conversation about diversity and inclusion has been ramped in some STEM graduate programs that are working with faculty and students to create a collaborative and discrimination-free environment. Many universities have expressed solidarity by producing statements addressing these racial injustices with discussions about modifying their Diversity and Inclusion Committees (DNI). However, it is not enough to have performative Diversity and Inclusion Committees that have discussionsevery once in a whileabout racial biases that have infiltrated systems of higher education. We want to see actionable items to change academic environments that negatively impact Black graduate students through policy modifications. I and many other Black graduate students have been met with many cultural competency issues from administrators who have greeted us as Dear minority graduate students in emails. White peers have made negative rebuttals and statements of hate about student organizations bringing light to the Black Lives Matter movement.

If institutions of higher learning want to be allies to Black graduate students, they need to address their own racial biases. Do not only consider our voices when you want feedback on your DNIgrants, butask us to give talks on our research or consider us for administrativepositions. Black faculty should be considered in the hiring process and tenured. Universities need to commit to increasing Black student representation in STEM PhD programs and train their staff on how to communicate with Black student recruits. When Black students enter their PhD programs, mental health resources and trained mentors should be accessible and promoted. Also, listen to Black students when we report instances of mistreatment from our PIs or superiors. Recall instances where you as a non-Black faculty member may have been complicit in this mistreatment by not reprimanding the offender for their actions. It should be mandatory for all faculty to attend training on cultural competency and courses on racism in higher learning, so they are more equipped to support Black graduate students through their journey.

We are living through a racial inequality crisis and non-Black students and academics must join in this fight and defend those who are the most vulnerable. Black students should not be the only ones fighting within their institutions for equity and justice.Werenot here for your quotas. Black students matter. Our people matter.

Paige Greenwoodis a rising 5th-year Neuroscience Doctoral Candidate at the University of Cincinnati College of Medicine and co-founder of the University of Cincinnati Science Policy Group.Paiges research focuses on the role of socioeconomic status on the behavioral and neurobiological correlates of reading for school-age children at the Cincinnati Childrens Hospital Medical Center. She became interested in science policy through her science outreach teaching elementary school children of color about neuroscience in Cincinnati Public Schools. She aims to understand how she can use her neuroscience background to advocate for STEM educational reform for marginalized and low-income communities.

Science Network Voices gives Equation readers access to the depth of expertise and broad perspective on current issues that our Science Network members bring to UCS. The views expressed in Science Network posts are those of the author alone.

Posted in: Science and Democracy Tags: Black in the ivory, Black lives matter, diversity in STEM, early career scientist

Support from UCS members make work like this possible. Will you join us? Help UCS advance independent science for a healthy environment and a safer world.

Continue reading here:
I Chose Protesting for Black Lives Matter Over Writing My PhD Dissertation - Union of Concerned Scientists

The Amalgamation of Human Brain and Artificial Intelligence – Analytics Insight

The human brain has advanced over time in countering survival instincts, harnessing intellectual curiosity, and managing authoritative ordinances of nature. When humans got an idea about the dynamics of the environment, we started with our quest to replicate nature.

While the human brain discovers ways to go beyond our physical capabilities, the combination of mathematics, algorithms, computational methods, and statistical models accumulated momentum after Alan Mathison Turing built a mathematical model for biological morphogenesis, and published a seminal paper on computing intelligence.

Today, AI has developed from data models for problem-solving to artificial neural networks, a computational model predicated on the structure and functions of human biological neural networks.

The brain, customarily perceived as an organ of the human body, should be understood as a biologically predicated form of artificial intelligence (AI). This proposition was surmised by the progenitors of AI in the 1950s, though it has been generally side-lined over the course of AIs history. However, developments in both neuroscience and more conventional AI make it fascinating to consider the issue anew.

The history of neuroscience has shown both tendencies from its inception, not least in terms of the alternative functions performed by the characteristic technologies of the AI field.

Understanding the complete impacts of this distinction needs eluding from the reductionist problematic that perpetuates to haunt philosophical discussions of neurosciences aspirations as a mode of inquiry

The early prospect, which will help to build machines possessing intelligence of humans, found inspiritment in three main directions.

Firstly, proof that the functioning of the human brain and nervous system, while astonishingly perplexed from a biological perspective, is predicated on elementary all-or-nothing procedures of the type that can facilely be copied by digital electronic circuits.

Secondly, the growth of symbolic logic and formal languages that are able to communicate immense components of higher mathematics, recommending that all human reasoning might be ultimately abbreviated to similar manipulating strings of symbols according to sets of rules. Such formal operations can probably easily be imitated by a digital computer.

Thirdly, the outlook of creating faster electronic calculating devices. With regard to this, developments since the 1950s have rarely been saddening. The density of switching elements of todays microchips surpasses that of neurons in the brain.

Artificial intelligence makes industrial machines and equipment precise, credible and self-healing, making strides calibrated performance imitating human action. AI incorporates robotic controls, vision-based sensing, and geospatial systems in order to automate advanced frameworks. It improves disease detection and prevention along with its treatment, amplifies engineering systems and handles self-organizing supply chains.

We, humans, are dependent on machines for decision-making for various processes like underwriting, recruitment, fraud detection, maintenance, etc. Real Core Energy deploys machine learning that assesses production as well as performance factors to better conduct oil drilling operations and investment decisions.

Though artificial intelligence has become indispensable in almost all fields today, the presiding approaches to artificial intelligence are based in false conceptions about the nature of the mind and of the brain as a biological organ.

Sadly, the superficial models of the brain and mind, which were the initial Kickstarter of artificial intelligence, have now become the paradigm for everything called cognitive science, as well as a huge part of neurobiology. It has become a standard protocol to levy methods, concepts, models and vocabulary from the domain of artificial intelligence, computer science onto the research of the brain and the mind. It is difficult to discover a scientific paper on these subjects which does not contain terms like computing, processing, circuits, storage and retrieval of information, encoding decoding etc.

Computational neuroscience connects human intelligence and artificial intelligence by developing theoretical models of the human brain for multiple studies on its functions, including vision, motion, sensory control, and learning.

Studies in human cognition are uncovering a deeper comprehension of our nervous system and its compound processing abilities. Models that provide high-level insights into memory, data processing, and speech/object recognition are simultaneously reshaping AI.

The integration of human intelligence with artificial intelligence will evolve computers into superhumans or humanoids that go far beyond human abilities. However, it needs computing models that combine visual and natural language processing, just how the brain functions, for comprehensive communication.

Neuroscience has made significant contributions to strengthen AI research and gain its increasingly important relevance. In planning for the future amalgamation of the two fields, it is essential to value that the past contributions of neuroscience to AI have hardly consisted of a simple shift of complete solutions which can be simply re-implemented in machines. Rather, neuroscience has often been useful in a precise way, facilitating algorithmic-level questions about qualities of animal learning and intelligence of interest to AI researchers and offering initial drives toward applicable mechanisms.

Excerpt from:
The Amalgamation of Human Brain and Artificial Intelligence - Analytics Insight

Blood-based biomarker can detect, predict severity of traumatic brain injury – National Institutes of Health

News Release

Wednesday, July 8, 2020

A study from the National Institutes of Health confirms that neurofilament light chain as a blood biomarker can detect brain injury and predict recovery in multiple groups, including professional hockey players with acute or chronic concussions and clinic-based patients with mild, moderate, or severe traumatic brain injury. The research was conducted by scientists at the NIH Clinical Center, Bethesda, Maryland, andpublished in the July 8, 2020, online issue ofNeurology.

After a traumatic brain injury, neurofilament light chain breaks away from neurons in the brain and collects in the cerebrospinal fluid (CSF). The scientists confirmed that neurofilament light chain also collects in the blood in levels that correlate closely with the levels in the CSF. They demonstrated that neurofilament light chain in the blood can detect brain injury and predict recovery across all stages of traumatic brain injury.

Currently, there are no validated blood-based biomarkers to provide an objective diagnosis of mild traumatic brain injury or to predict recovery, said Leighton Chan, M.D., M.P.H., chief of the Rehabilitation Medicine Department at the NIH Clinical Center. Our study reinforces the need and a way forward for a non-invasive test of neurofilament light chain to aid in the diagnosis of patients and athletes whose brain injuries are often unrecognized, undiagnosed or underreported.

The study examined multiple groups including professional hockey players in Sweden with sports-related concussions, hockey players without concussions, hockey players with persistent post-concussion symptoms, non-athlete controls, and clinic-based patients at the NIH Clinical Center who were healthy or with acute, subacute, and chronic mild traumatic brain injuries. The study showed that neurofilament light chain in the blood:

In the clinic-based patients, the levels of blood neurofilament light chain at five years after a single mild, moderate, or severe traumatic brain injury were significantly increased compared to healthy controls. This suggests that even a single mild traumatic brain injury (without visible signs of structural damage on a standard clinical MRI) may cause long-term brain injury, and serum neurofilament light could be a sensitive biomarker to detect even that far out from initial injury.

This study is the first to do a detailed assessment of serum neurofilament light chain and advanced brain imaging in multiple cohorts, brain injury severities, and time points after injury, said the studys lead author, Pashtun Shahim, M.D., Ph.D., NIH Clinical Center. Our results suggest that serum neurofilament light chain may provide a valuable compliment to imaging by detecting underlying neuronal damage which may be responsible for the long-term symptoms experienced by a significant number of athletes with acute concussions, and patients with more severe brain injuries.

The study was funded by the Intramural Research Program at NIH, the Department of Defense Center for Neuroscience and Regenerative Medicine at the Uniformed Services University, and the Swedish Research Council.

Traumatic brain injury is a major leading cause of death and disability in the United States with more than 2.87 million emergency department visits, hospitalizations and deaths annually. While majority of all traumatic brain injuries are classified as mild (also known as a concussion), it remains difficult to diagnose this condition. There are a wide range of variable behavioral and observational tests to help determine a patients injuries but most of these tests rely on the patient to self-report signs and symptoms. Also, imaging has limitations with detecting micro-structural injuries in the brain.

About the NIH Clinical Center:The NIH Clinical Center is the worlds largest hospital entirely devoted to clinical research. It is a national resource that makes it possible to rapidly translate scientific observations and laboratory discoveries into new approaches for diagnosing, treating, and preventing disease. Over 1,600 clinical research studies are conducted at the NIH Clinical Center, including those focused on cancer, infectious diseases, blood disorders, heart disease, lung disease, alcoholism and drug abuse. For more information about the Clinical Center, visit https://clinicalcenter.nih.gov/index.html.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

See the original post:
Blood-based biomarker can detect, predict severity of traumatic brain injury - National Institutes of Health

Off The Beaten Path: Lickity Split – Journal & Topics Newspapers Online

Stick it out and say, Ahhhhhh!

If the face of Helen of Troy was responsible for launching a thousand ships according to playwright Christopher Marlowe, and the eyes were the mirror of the soul to novelist Paulo Coelho De Souza, and the ears were accredited as the last feature to age by visionary Malcolm de Channel, and loose lips could sink ships, and the nose knows well then, what about the tongue, that very curious pinkish impish body part inside our skulls?

Perhaps not as physically attractive as other features, the tongue is certainly an important part of the human anatomy. Dr. Sam Webster, senior lecturer in anatomy and embryology, Swansea University Medical School in the United Kingdom, explains in his Muscles of the Tongue Anatomy presentation that the tongue is comprised of eight muscles.

The eight muscles are categorized into two groups, intrinsic and extrinsic. The four intrinsic muscles, the superior longitudinal muscle, the inferior longitudinal muscle, the vertical muscle, and the transverse muscle, alter the shape of the tongue, running along the length not attached to bone. The four extrinsic muscles, the genioglossus, hyoglossus, styloglossus, and palatoglossus, change the position of the tongue and are anchored to bone.

The tongue performs continuously like the heart. Even when sleeping, the tongue pushes saliva down the throat. We know that the tongue plays an important role in tasting and breaking down food, swallowing and speech. Thanks to the tongue containing inguinal tonsils, germs are filtered out of the body. The medical community describes the tongue as a mass of interlacing skeletal muscle connective tissue with some mucous and serous glands, and pockets of adipose tissue, covered in oral mucosa. Like a fingerprint and snowflakes, each individuals tongue print is unique.

Writer Josh Dulaney in his article Why your tongue isnt as necessary as you might have thought explains that Cal State University has been involved in research concerning humans born with a very rare condition called isolated congenital aglossia, meaning without a tongue. Cal States Betty McMicken, associate professor in the department of Speech-Language Pathology, and Long Wang, assistant professor in the department of Family and Consumer Sciences, worked with Kelly Rogers, a Saddleback College student who was born without a tongue but is still able to speak and detect basic tastes. Rogers muscles on the floor of her mouth have compensated for her loss of a tongue without medical intervention. Wang refers to it as the natural condition, the natural progression. Such discoveries give hope to those who have no tongues or who have had partial removals.

The adult mans average tongue length is 3.3 inches and the average womens length is 3.1 inches. The Guinness World Records reports the title of the Worlds Longest Tongue belonging to Nick Stoeberl, measuring in at 3.97 inches. Some competition has curled up with a young woman, Adrianne Lewis, claiming a 4-incher that can reach her eye!

While were talking tongue, there is no denying the popularity of Mick Jagger and the Rolling Stones very famous and familiar Tongue and Lip Design logo, which came to be referred to as the Stones Tongue, created by British art designer John Pasche. The notorious image depicts cartoon-like parted lips, white top teeth, and a tongue protruding in a downward position. Studying at the Royal College of Art, Pasche started working with Mick Jagger and the Rolling Stones while he was still a student in 1969. Rolling Stone reports Pasche explaining, The design concept for the Tongue was to represent the bands anti-authoritarian attitude, Micks mouth and the obvious sexual connotations. (The coronavirus has put a damper on some of the 50-year anniversary events acknowledging the famous logo.)

According to Best Classic Bands website (bestclassicbands.com): Pasche who had previously designed posters for several British films and Jagger met, and the artist was shown a piece of artwork depicting the Indian goddess Kali, whose tongue was sticking out in the painting. Pasche went to work and came up with the tongue and lips design, now so ubiquitous (the bright red was added later by an Atlantic Records executive).

Revolutionary for its time, the Stones tongue image worked well with the rock group with its lead singer gyrating on the stage, singing nasty lyrics about unmentionables, and seemingly implying some form of oral sex. Simple and kind of crude, the design has lived on through the years. Because the logo debuted in the Stones Sticky Fingers album package, many people incorrectly believed that cover designer Andy Warhol came up with it. (Warhols cover design featured a picture of the bulging crotch of Joe Dallesandro, an artist in tight jeans with a prominent zipper!) Craig Braun, designer, actor, and all-around Chicago born entrepreneur is often considered as a co-designer of the tongue image as he played a major role in the Sticky Fingers packaging and design.

Branded forever, the Stones tongue design was voted in August 2008 as the greatest band logo of all time in a poll conducted by Gigwise, a British online music news site that features music news, photos, album reviews, music festivals, and concert tickets. The logo which Pasche said took him a week to finish earned him a total of approximately 250 pounds of sterling (today about $312).

And the beat goes on with the popular American band Maroon 5 immortalizing the Stones Tongue in their 2010 hit song Moves Like Jagger:

Take me by the tongue and Ill know you/Kiss me till youre drunk and Ill show you/Got them moves like Jagger/I got the moves like Jagger, I got the mooooooooves like Jagger

Until we meet again, as James of Scotland would say, Keep well thy tongue.

See more here:
Off The Beaten Path: Lickity Split - Journal & Topics Newspapers Online

Early fertility preservation in patients with endometriosis helps increase their chances of pregnancy – PRNewswire

VALENCIA, Spain, July 9, 2020 /PRNewswire/ -- Endometriosis is a disease that can seriously compromise ovarian function and can therefore pose a threat to the fertility of women who suffer from it. In fact, approximately 50% of patients with endometriosis will experience infertility; therefore, preserving fertility in this population should definitely be considered.

"Last April we presented a study showing the suitability oocyte vitrification in patients with endometriosis to preserve their fertility. In cases where ovarian surgery was required, the highest success rates were observed when the oocytes were vitrified prior to surgery, especially in patients under 35 years of age. As several scientific publications show, this is due to the fact that, even in very expert hands, cystectomy can cause a decrease of up to 40% in serum AMH levels, reflecting a significant impairment of the ovarian reserve as a result of the endometriosis removal surgery, or because in addition to removing the cyst, healthy tissue may also be removed inadvertently. However, it is not known whether the survival of the oocytes and the clinical outcomes would be negatively affected in patients with endometriosis who preserved their fertility compared to women without endometriosis who vitrified their oocytes for social reasons?" asked Dr Ana Cobo, Director of IVI Valencia's Cryobiology Unit.

This was the starting point for the study entitled Oocyte survival and clinical outcome is impaired in young endometriosis patients after fertility preservation (FP), led by Dr. Cobo, and which is presented at the 36th edition of the European Society of Human Reproduction and Embryology (ESHRE) Congress.

"The results of this study showed similar success rates in patients over 35 years of age, but in the under 35 group we observed that all parameters analyzed worse off in women with endometriosis. One might think that this finding is due to the fact that patients with endometriosis may have fewer eggs, and yes, this is one of the reasons, but not the only one. The truth is that the implantation rate, which does not depend on the number of oocytes, is about 15 points lower (39% in endometriosis vs. 55% in preservation for social reasons), which may be related to oocyte quality. The oocyte survival rate (85% in endometriosis vs. 91% in social preservation) reinforces this thesis," added Dr. Cobo.

In this sense, the results of survival, implantation and the lower reproductive potential observed in young patients with endometriosis confirm the negative impact of the disease on the ovarian reserve and most probably on the quality of the oocytes. To this we add the morphokinetic alterations observed by other authors in the embryos of patients with endometriosis, suggesting a poorer quality embryo.

This is a retrospective work that included 485 women with endometriosis who preserved their fertility, a sample from the study previously presented, compared to the 641 women who preserved for social reasons -without endometriosis-, a sample from the study that Dr. Cobo published in 2018. All of them used their vitrified oocytes subsequently to achieve pregnancy.

"Despite the high incidence of endometriosis and the growing number of women suffering from this disease who have vitrified oocytes to safeguard their fertility, very little is known about the effectiveness of the strategy in these cases. This study helps us clarify some of the main questions regarding the impact of endometriosis on reproductive outcomes. The study findings will also help us in advising these patients regarding their prospect of becoming mothers with their own eggs. They should preserve their fertility at an early age to increase their chances of pregnancy. Knowing that not only surgery can be harmful to the ovarian reserve, but also that endometriosis can alter the quality of the eggs, negatively affecting the rate of gestation, the sooner they are preserved, the greater the chance of success,"concluded Dr. Cobo.

About IVIRMA Global

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to assisted reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest technologies. In early 2017, IVI merged with RMANJ, becoming the largest assisted reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for reproductive medicine. http://www.ivi.es- http://www.rmanetwork.com.

CONTACT: Olesia Plokhii, (617) 997-8779, [emailprotected]

SOURCE IVIRMA Global

http://www.ivirma.com

Read more here:
Early fertility preservation in patients with endometriosis helps increase their chances of pregnancy - PRNewswire

I met my sperm donor birth father after years of wondering and was left crushingly disappointed – Telegraph.co.uk

What I remember most about meeting my father for this first time was his opening gambit: This pub is one of my favourites. He gestured to a picnic bench and asked me if I wanted a beer.

I was conceived by anonymous donor sperm and for years Id fantasised about meeting my biological father in my head hed loomed large, like an astronaut or Nobel laureate. The only things that my biological mother, Miranda, and her partner Dawn, knew about the donor was that he was green eyed and a medical student. Yet the man I met was an ordinary, unremarkable 50-year old who worked in human resources (turns out he actually had blue eyes and had studied economics), and the entire conversation as we fished around for topics we might have in common and found very few was crushingly disappointing.

He chatted awkwardly about draft beer and football, while I told him about being raised by lesbian mums and my career, and by the time I left the pub in north London, I felt shaken. Far from making me wish Id had a relationship with this man, the experience only made me miss Dawn, who Id always seen as a parent figure and who had died two years earlier. I remember calling Mum and crying down the phone. Hes a nice enough man, but hes not Dawn, I admitted. And yet I decided to give it another shot and meet up with him again.

Id known I didnt have a father for as long as I can remember and for years Id felt OK about it. Back in 1992 when I was born, being conceived by sperm donation was still an oddity, as was being raised by same-sex parents. Our house in the suburbs of Bristol was in a traditional neighbourhood with 2.4-children families and I remember making up ridiculous stories, as a very little kid, to account for being fatherless: my dad being a sailor, for example, who had died at sea. But my creative lesbian home was a haven and we did lots of dressing up and art.

When my mum split up with Dawn, when I was around six, and got together with Jayne, a woman who was visibly more masculine, and loud and proud at the school gates, I started being bullied. I think kids picked up on the fact that there was something different about me from their gossipy parents. A Christian woman who ran the after-school club was especially cruel. I ended up moving schools because I was being picked on.

There were plenty of upsides about having three mums. When I came out as liking boys at the age of 11, they were unsurprised and very supportive. And I knew how much they loved me. Yet there was always a niggling fear, when I was a child, about being incomplete: a fatherless boy without dad to take me to football or show me the ropes. This absent biological father became a mythical godlike figure until my teens when everything changed. It was the 2000s and being from an alternative family was suddenly cool. When another boy with two mums joined my secondary school, I remember being livid: having two mums was mysuperpower.

I always knew that at 18 Id be able to write to the HFEA (Human Fertility and Embryology Authority) for more information about the man who had donated the sperm, but I didnt hold out hope. Back then, sperm could be donated anonymously and only if the donor chose to waiver it could the child apply for the information once theyd turned 18 (although a change in the law means that children conceived after 2005 have an automatic right to know their donors identity). Id read up a little on the statistics and found that only one in ten sperm donors waive their right to anonymity. I wrote off on my 18th birthday and discovered that although there was no news about my donor, I had five donor siblings, two of whom were happy to be contacted. Oddly however, I couldnt get excited about this revelation, as the donor was the one who Id fixated on.

Even so, a few years later, when I was in my early 20s, I decided to track down my half-siblings, mainly as material for my work when I was writing a play about being a donor child. But as I set this up with the HFEA, they sent me the shock news that there had been a mixup and my father WAS able to be contacted after all. I felt a mixture of queasiness and excitement. It was a strange time to hear the news as Dawn had died of cancer a couple of years earlier. Id dearly loved her and considered her a parent and now, suddenly, here was another parent figure emerging.

Looking back, I should have let it all sink in before deciding whether to meet him but I went ahead immediately, after checking with Mum first. I was anxious: would it seem like a betrayal? She seemed excited but worried, though she put on a supportive front.

Desperate to meet him, I carefully hand-wrote a letter to him thanking him for his involvement in my life, enclosing a photo and my email and tentatively suggesting we meet for coffee. It took him less than a week to email back - and it was a pretty nail-biting time. I spent it obsessively Googling him, looking into his career history as well as finding a small pixelated headshot. Mum helped with the research and I loved that she was so much a part of it all

By the time we finally met, my nerves were still raw. Id told friends in London about it and my then-partner, and they were all supportive. The problem was that they couldnt really understand how it felt to meet this man that was so instrumental in my being, but wasnt a dad. Mum advised me not to get my hopes up in advance of the meeting, adding be yourself Jordan, thats enough.

After the shock of discovering this man I had built up in my head was an ordinary bloke, it struck me that were were oddly similar in some ways, particularly our mannerisms like the way he moved his hands and gazed off into the near distance and his prominent nose that was far more like mine than my Mums dainty button one.

I asked what compelled him to become a donor - he had donated five times - and when he admitted that it was for the money as hed been a student at the time and that hed only come forward because of his Catholic beliefs, it hurt. Happily he was very unjudgmental about my lesbian mums. It would have been tough if there had been any note of homophobia, or disapproval.

We groped around for other things we might have in common: politics, work, social attitudes, and found very little. He was into money and cars while I had stayed true to my chickpea-eating hippy roots instilled in me by my Mums.

We left it hanging but I could sense he wanted to meet me again. So we kept in touch and a few months later he suggested we meet again. By this point the swell of disappointment had subsided and I thought: why not?

It made me even more grateful to my mum and Dawn for the way they raised me and how loving my upbringing had been. On some level, I thought that meeting him would heal the emotions around Dawns death, but instead it had starkly reminded me of what Id lost. I became depressed and only got through it with the help of my mum and my two half sisters, conceived from the same donor. Id met up with them in person shortly before I met the donor - theyd also met him in person - they were both thoughtful women, born within a week of me [same year] and we shared personality traits and understood each other like no one else could: we had been through the same emotional ups and downs, high expectations and crashing disappointments of meeting our sperm donor and they were extremely supportive.

Looking back at it all, I feel conflicted. Being a sperm donor child is quite new and society projects all sorts of baggage onto us of being somehow lacking, and that can be tough. What does it mean if we dont feel fatherless? And if we do, is that in some way a rejection of the parents who raised us?

Ive seen my donor a few times since that first meeting and were building a relationship, of sorts, at a distance. Hes part of the puzzle that made me but hell never be my dad, and thats OK. I had all the parenting a boy could need. Meeting the donor has affected my relationship with mum in a lovely way: we were close before but now we share everything. Sometimes what were searching for is in front of us all along.

More here:
I met my sperm donor birth father after years of wondering and was left crushingly disappointed - Telegraph.co.uk